Effect of beclomethasone dipropionate (BDP) as extrafine aerosol on bronchoalveolar lavage (BAL) lymphocytes in chronic sarcoidosis

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 22, Issue 3, 2005, Pages 214-221

  Ludwig Sengpiel, Andrea ^a   Jaksztat, Elke ^b   Welker, Lutz ^b   Zeschnigk, Thomas ^b   Kanniess, Frank ^a   Jörres, Rudolf A ^b,c   Magnussen, Helgo ^a,b   Kirsten, Detlef ^b  

^a Pulmonary Research Institute   (Germany)

^b KRANKENHAUS GROSSHANSDORF   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Corticosteroid; Cytokine production; Inhalation therapy; Interstitial lung disease; Radiological staging; Serum markers

Indexed keywords

BECLOMETASONE DIPROPIONATE; CARBON MONOXIDE; CYTOKINE; PLACEBO;

ADULT; AEROSOL; ARTICLE; CELL COUNT; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HLA MATCHING; HUMAN; LUNG DIFFUSION CAPACITY; LUNG LAVAGE; LYMPHOCYTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SARCOIDOSIS; THORAX RADIOGRAPHY;

ADMINISTRATION, INHALATION; ADULT; AEROSOLS; BECLOMETHASONE; BRONCHOALVEOLAR LAVAGE FLUID; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; PLACEBOS; RESPIRATORY FUNCTION TESTS; SARCOIDOSIS, PULMONARY;

EID: 27944468317     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Yamamoto M, Sharma OP, Hosoda Y: Special report: the 1991 descriptive definition of sareoidosis. Sarcoidosis 1992; 9: 33-4.
2. Hunninghake GW, Crystal RG: Pulmonary sarcoidosis: a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity. N Engl J Med 1981; 305: 429-34.
3. Semenzato G, Pezzutto A, Chilosi M, Pizzolo G: Redistribution of T-lymphocytes in the lymph nodes of patients with sarcoidosis. N Engl J Med 1982; 306: 48-9.
4. Agostini C, Trentin L, Zambello R, et al: CD8 alveolitis in sarcoidosis: incidence, phenotypic characteristics, and clinical features. Am J Med 1993; 95: 466-72.
5. Hunninghake GW, Costabel U: American Thoracic Society: Statement on sarcoidosis. Am J Respir Crit Care Med 1999; 160: 736-55.
6. Morey SS: American Thoracic Society issues consensus statement on sarcoidosis. Am Fam Physician 2000; 61: 553-4, 556.
7. Selroos O: Treatment of sarcoidosis. Sarcoidosis 1994; 11: 80-3.
8. Gottlieb JE, Israel HL, Steiner RM, Triolo J, Patrick H: Outcome in sarcoidosis: the relationship of relapse to corticosteroid treatment. Chest 1997; 111: 623-31.
9. Paramothayan S, Jones PW: Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA 2002; 287: 1301-7.
10. Mana J, Montero A, Vidal M, Marcoval J, Pujol R: Recurrent sarcoidosis: a study of 17 patients with 24 episodes of recurrence. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 212-21.
11. Selroos O, Löfroos AB, Pietinalho A, Niemistö M, Riska H: Inhaled budesonide for maintenance treatment of pulmonary sarcoidosis. Sarcoidosis 1994; 11: 126-31.
12. Alberts C, van der Mark TW, Jansen HM: Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study. Dutch Study Group on Pulmonary Sarcoidosis. Eur Respir J 1995; 8: 682-8.
13. Comments in: Eur Respir J 1995; 8: 679-81
14. Eur Respir J 1996; 9: 180-1.
15. Erkkilä S, Fröseth B, Hellström PE, et al: Inhaled budesonide influences cellular and biochemical abnormalities in pulmonary sarcoidosis. Sarcoidosis 1988; 5: 106-10.
16. Spiteri MA, Newman SP, Clarke SW, Poulter LW: Inhaled corticosteroids can modulate the immunopathogenesis of pulmonary sacroidosis. Eur Respir J 1989; 2: 218-24.
17. Bencic D, Batinic D, Cucevic I, Boranic M, Miculinic N: The role of T-lymphocyte subpopulation in bronchoalveolar lavage in pulmonary parenchyma diseases. Sarcoidosis 1990; 7: 106-9.
18. Gupka SK: Treatment of sarcoidosis patients by steroid aerosol: a ten-year prospective study from Eastern India. Sarcoidosis 1989; 6: 51-4.
19. Zych D, Pawlicka L, Zielinski J: Inhaled budesonide vs. prednislone in the maintenance treatment of pulmonary sarcoidosis. Sarcoidosis 1993; 10: 56-61.
20. Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O: Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled multicenter study. Finnish Pulmonary Sarcoidosis Study Group. Chest 1999; 116: 424-31.
21. Comment in: Chest 2000; 118: 567.
22. Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O; Finnish Pulmonary Sarcoidosis Study Group: Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest 2002; 121: 24-31.
23. Comment in: Chest 2002; 121: 3-5.
24. Baughman RP, Iannuzzi MC, Lower EE, et al: Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 198-204.
25. Milman N, Graudal N, Grode G, Munch E: No effect of high-dose inhaled steroids in pulmonary sarcoidosis: a double-blind, placebo controlled study. J Int Med 1994; 236: 285-90.
26. Milman N: Oral and inhaled corticosteroids in the treatment of pulmonary sarcoidosis - a critical reappraisal. Sarcoidosis Vasc Diffuse Lung Dis 1998; 15: 150-7.
27. Herer B: Failure of inhaled corticosteroids to improve small airway obstruction in two patients with sarcoidosis. Respiration 2002; 69: 107-8.
28. Leach CL: Improved delivery of inhaled steroids to the large and small airways. Respir Med; 1998; 92 (suppl A):3-8.
29. Marshall BG, Wangoo A, Harrison LI, Young DB, Shaw RJ: Tumour necrosis factor-alpha production in human alveolar macrophages: modulation by inhaled corticosteroid. Eur Respir J 2000; 15: 764-70.
30. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC: Lung volumes and forced ventilatory flows. Eur Respir J 1993; 16 (suppl): 5-40.
31. Singh A Zelazowska EB, Petrides JS, et al: Lymphocyte subset responses to exercise and glucocorticoid suppression in healthy men. Med Sci Sports Exerc 1996; 28: 822-8.
32. Costabel U, Hunninghake GW: ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. Eur Respir J 1999; 14:735-7.
33. Chang JA, Curtis JR, Patrick DL, Raghu G: Assessment of health-related quality of life in patients with interstitial lung disease. Chest 1999; 116: 1175-82.
34. Comment in: Chest 2000; 118: 275.
35. American Thoracic Society: Single breath carbon monoxide diffusing capacity. Recommendations for a standard technique. Am Rev Respir Dis 1987; 136: 1299-307.
36. Klech H, Hutter C, Costabel U, eds: Clinical guidelines and indications for bronchoalveolar lavage (BAL). Eur Respir Rev 1992; 2: 47-127.
37. Krug N, Madden J, Redington AE, et al: T-cell cytokine profile evaluated at the single cell level in BAL and blood in allergic asthma. Am J Respir Cell Mol Biol 1996; 14: 319-26.
38. Comment in: Am J Respir Cell Mol Biol 1996; 14: 316-8.
39. Sharma SK, Khanna M, Sharma S, et al: Effect of corticosteroid treatment on various serological & bronchoalveolar lavage abnormalities in patients with sarcoidosis. Indian J Med Res 1995; 101: 207-12.
40. Chadelat K, Baculard A, Grimfeld A, et al: Pulmonary sarcoidosis in children: serial evaluation of bronchoalveolar lavage cells during corticosteroid treatment. Pediatr Pulmonol 1993; 16: 41-7.
41. Hol BE, Hintzen RQ, Van Lier RA, Alberts C, Out TA, Jansen HM: Soluble and cellular markers of T cell activation in patients with pulmonary sarcoidosis. Am Rev Respir Dis 1993; 148: 643-9.
42. Planck A, Katchar K, Eklund A, Gripenback S, Grunewald J: T-lymphocyte activity in HLA-DR17 positive patients with active and clinically recovered sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 110-17.
43. Wahlström J, Berlin M, Skold CM, Wigzell H, Eklund A, Grunewald J: Phenotypic analysis of lymphocytes and monocytes/macrophages in peripheral blood and bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Thorax 1999; 54: 339-46.
44. Katchar K, Wahlström J, Eklund A, Grunewald J: Highly activated T-cell receptor AV2S3(+) CD4(+) lung T-cell expansions in pulmonary sarcoidosis. Am J Respir Crit Care Med 2001; 163: 1540-5.
45. Möllers M, Aries SP, Drömann D, Mascher B, Braun J, Dalhoff K: Inrracellular cytokine repertoire in different T cell subsets from patients with sarcoidosis. Thorax 2001; 56: 487-93.
46. Wahlström J, Katchar K, Wigzell H, Olerup O, Eklund A, Grunewald J: Analysis of intracellular cytokines in CD4+ and CD8+ lung and blood T cells in sarcoidosis. Am J Respir Crit Care Med 2001; 163: 115-21.
47. Prasse A, Georges CG, Biller H, et al: Th1 cytokine pattern in sarcoidosis is expressed by bronchoalveolar CD4+ and CD8+ T cells. Clin Exp Immunol 2000; 122: 241-8.
48. Milburn HJ, Poulter LW, Dilmec A, Cochrane GM, Kemeny DM: Corticosteroids restore the balance between locally produced Th1 and Th2 cytokines and immunoglobulin isotypes to normal in sarcoid lung. Clin Exp Immunol 1997; 108: 105-13.
49. Prior C, Haslam PL: Increased levels of serum interferon-gamma in pulmonary sarcoidosis and relationship with response to corticosteroid therapy. Am Rev Respir Dis 1991; 143: 53-60.
50. Salmeri FM, Sofo V, Ando FG, et al: Imbalance of serum cytokine network in sarcoid patients: index of sarcoidosis relapse? Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 53-61.
51. Ziegenhagen MW, Benner UK, Zissel G, Zabel P, Schlaak M, Müller-Quernheim J: Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med 1997; 156: 1586-92.
52. Drent M, Jacobs JA, de Vries J, Lamers RJ, Liem IH, Wouters EF: Does the cellular bronchoalveolar lavage fluid profile reflect the severity of sarcoidosis? Eur Respir J 1999; 13: 1338-44.
53. Mihailovic-Vucinic X, Zugic V, Videnovic-Ivanov J: New observations on pulmonary function changes in sarcoidosis. Curr Opin Pulm Med 2003; 9: 436-41.